Clinical Research Directory
Browse clinical research sites, groups, and studies.
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
Sponsor: BioXcel Therapeutics Inc
Summary
This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.
Official title: A Randomized, Double-blind, Placebo-controlled Study to Determine Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
Key Details
Gender
All
Age Range
10 Years - 17 Years
Study Type
INTERVENTIONAL
Enrollment
140
Start Date
2021-08-27
Completion Date
2026-12-31
Last Updated
2026-04-03
Healthy Volunteers
No
Conditions
Interventions
BXCL501 80 Micrograms
Sublingual film containing 80 Micrograms BXCL501
Placebo Film
Matching Sublingual Placebo film
BXCL501 120 Micrograms
Sublingual film containing 120 Micrograms BXCL501
BXCL501 60 Micrograms
Sublingual film containing 60 Micrograms BXCL501 Europe Only
Locations (5)
BioXcel Clinical Research Site
Anaheim, California, United States
Bioxcel Clinical Research Site
Hialeah, Florida, United States
BioXcel Clinical Research Site
Atlanta, Georgia, United States
Bioxcel Clinical Research Site
Decatur, Georgia, United States
BioXcel Clinical Research Site
DeSoto, Texas, United States